Journals / Anadolu Kardiyoloji Dergisi / 2008 / Cilt: 8 - Sayı: 3

Statins in stroke prevention

İnmenin önlenmesinde statinler

Pages
217–222
Publication Date
2022-10-10
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

In this review, we will discuss the effects of statins on stroke and the potential mechanisms of action.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Cholesterol lowering with statins has been proven to reduce vascular events in primary and secondary prevention of coronary artery disease (CAD).
📊
Key Findings & Data:However, randomized trials in patients with CAD have shown that statins decrease stroke incidence.
💡
Conclusion & Impact:In this review, we will discuss the effects of statins on stroke and the potential mechanisms of action.
🔬Design:Review & Systematic Survey
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters

Abstract

Cholesterol lowering with statins has been proven to reduce vascular events in primary and secondary prevention of coronary artery disease (CAD). Epidemiologic studies found no or little association between blood cholesterol levels and stroke. However, randomized trials in patients with CAD have shown that statins decrease stroke incidence. These statin trials indicate 21% relative risk reductions for stroke. In subgroup analysis of the Heart Protection Study, simvastatin had no effect on stroke recurrence, in patients with a previous stroke. Recently, Stroke Prevention by Aggressive Reduction in Cholesterol Levels study showed that treatment with high dose atorvastatin reduced risk of stroke in patients with recent stroke and transient ischemic attack and no known CAD. In this review, we will discuss the effects of statins on stroke and the potential mechanisms of action.

Özet

Statinlerle kolesterol düşürülmesi, koroner arter hastalığının (KAH) primer ve sekonder korunmasında vasküler olayları azaltmıştır. Epidemiyolojik çalışmalarda inme ile kolesterol düzeyleri arasında zayıf bir ilişki bulunmuştur. Statinler, KAH olan hastalarda inme insidansını azaltmıştır. Statin çalışmalarında inmede yaklaşık %21 oranında azalma elde edilmiştir. Heart Protection Study’nin bir altgrup analizinde, daha önce inme geçirenlerde simvastatin ile inme rekürrensinin azalmadığı bulunmuştur. Yakın zamanda yayınlanan Stroke Prevention by Aggressive Reduction in Cholesterol Levels çalışmasında ise, bilinen koroner arter hastalığı olmayan geçirilmiş inme ve geçici iskemik ataklı hastalarda yüksek doz atorvastatin tedavisinin inme rekürrensini azalttığı gösterilmiştir. Bu derlemede statinlerin inme tedavisindeki yeri ve muhtemel etki mekanizmaları tartışılacaktır.

🔖

Cite This Article

GEDİKLİ, Ö., BAYKAN, M. (2022). Statins in stroke prevention. Anadolu Kardiyoloji Dergisi, Cilt: 8 - Sayı: 3, 217–222. https://ajindex.com/articles/437048

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (13)

  1. Goldstein LB, Adams R, Alberts MJ, Appel LJ, Brass LM, Bushnell CD, et al. Primary prevention of ischemic stroke: a guideline from the American Heart Association/American Stroke Association Stroke Council: Stroke. 2006; 37: 1583-633
  2. American Heart Association. Heart Disease and Stroke Statistics-2004 Update. Dallas, Texas: American Heart Association; 2003
  3. Howard G, Howard VJ, Katholi C, Oli MK, Huston S. Decline in US stroke mortality: an analysis of temporal patterns by sex, race, and geographic region. Stroke. 2001; 32: 2213-20
  4. Iso H, Jacobs DR Jr, Wentworth D, Neaton JD, Cohen JD. Serum cholesterol levels and six-year mortality from stroke in 350,977 men screened for the multiple risk factor intervention trial. N Engl J Med 1989; 320: 904-10
  5. Kagan A, Popper JS, Rhoads GG. Factors related to stroke incidence in Hawaii Japanese men. The Honolulu Heart Study. Stroke 1980; 11: 14-21
  6. MuldoonMF, Manuck SB, Matthews KA. Lowering cholesterol concentrations and mortality: a quantitative review of primary prevention trials. BMJ 1990; 301: 309-14
  7. Kearney PM, Baigent C. Statins: Are any questions unanswered? Curr Opin Lipidol 2006;17 418-25
  8. Atkins D, Psaty BM, Koepsell TD, Longstreth WT Jr, Larson EB. Cholesterol reduction and the risk for stroke in men. A metaanalysis of randomized, controlled trials. Ann Intern Med 1993; 119: 136-45
  9. Scandinavian Simvastatin Survival Study Group. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet 1994; 344: 1383-9
  10. Sacks FM, Pfeffer MA, Moye LA, Rouleau JL, Rutherford JD, Cole TG, et al. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. N Engl J Med 1996; 336: 1001-9
  11. The Long-Term Intervention with Pravastatin in Ischaemic Disease (LIPID) Study Group. Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. N Engl J Med 1998; 339: 1349-57
  12. Shepherd J, Cobbe SM, Ford I, Isles CG, Lorimer AR, MacFarlane PW, et al. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. N Engl J Med 1995; 333: 1301-07
  13. Heart Protection Study Collaborative Group. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20536 high-risk individuals: a randomised placebo-controlled trial. Lancet 2002; 3